US-based Cook Medical has introduced its Zilver PTX drug-eluting stent in Canada for the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA).

The launch of the product was performed at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cook Medical Peripheral Intervention clinical division vice-president Mark Breedlove said launching Zilver PTX in Canada brings the benefits of drug-eluting stents to Canadian PAD patients.

“The device is a self-expanding metal stent coated with the drug paclitaxel.”

“We’re very pleased to be the company that introduces this technology in Canada,” Breedlove said.

The device is a self-expanding metal stent coated with the drug paclitaxel, which is absorbed by the surrounding tissues to prevent the growth of scar tissue that can reclog the artery.

Zilver PTX is indicated for use in treating new or recurring lesions as long as 140mm per leg.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In Canada, the company will sell Zilver PTX in 40mm, 60mm, 80mm and 100mm in lengths and in 6mm and 7mm diameters.

The four-year data from the international Zilver PTX randomised trial shows that 75% of patients treated with Zilver PTX maintained blood flow in the SFA at four years compared with 57.9% patency for patients who received a bare-metal Zilver stent.

The initial launch of Zilver PTX took place in 2009 and the device has since been used to treat more than 25,000 PAD patients.

Currently, the device is available in more than 50 countries across Europe, the Middle East, North and South America, and the Asia-Pacific region.